Welcome to our dedicated page for Rapport Therapeutics SEC filings (Ticker: RAPP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings page for Rapport Therapeutics, Inc. (Nasdaq: RAPP) provides access to the company’s official regulatory disclosures as a clinical-stage biotechnology issuer. Rapport’s common stock is registered under Section 12(b) of the Securities Exchange Act of 1934 and listed on The Nasdaq Global Market under the symbol RAPP, so its filings offer detailed information on its precision neuroscience business and capital markets activity.
Through this page, readers can review Form 10-K and Form 10-Q reports (when filed) for discussions of Rapport’s RAP technology platform, the development of RAP-219 for drug-resistant focal onset seizures, bipolar mania, and diabetic peripheral neuropathic pain, and additional programs in chronic pain, migraine, and hearing or vestibular disorders. These periodic reports also describe risk factors, research and development expenses, and other elements of the company’s operating profile.
Frequent Form 8-K filings from RAPP document material events such as positive Phase 2a trial results for RAP-219 in focal onset seizures, new data analyses presented at scientific meetings, public offerings of common stock under an effective shelf registration statement on Form S-3, and quarterly financial results and business updates. Some 8-Ks also summarize regulatory developments, including clinical holds, end-of-Phase 2 planning, and changes to at-the-market sales arrangements.
Investors can also use this page to locate information related to shareholder meetings and voting outcomes, as disclosed in 8-K items covering submissions of matters to a vote of security holders. Insider transaction reports on Form 4, when available, complement these filings by showing equity activity by directors and officers.
Stock Titan enhances these documents with AI-powered summaries that explain key points from lengthy filings, highlight clinical and financial milestones, and make it easier to understand how new disclosures may relate to Rapport’s RAP-219 program and broader precision neuroscience pipeline. Real-time updates from EDGAR help ensure that new RAPP filings, including 10-K, 10-Q, 8-K, and Form 4 submissions, are quickly accessible in one place.
Director James Healy of Rapport Therapeutics (RAPP) received a stock option grant for 21,850 shares of common stock on June 17, 2025. The options were granted with the following key terms:
- Exercise price set at $10.95 per share
- Expiration date of June 17, 2035
- Vesting occurs at earlier of June 17, 2026 or next Annual Meeting of Stockholders
- Vesting conditional on continued service as director
The transaction was reported via Form 4 filing and executed under standard compensation arrangements for non-employee directors. The filing was signed by Troy Ignelzi as attorney-in-fact on June 18, 2025. This equity grant aligns the director's interests with shareholders through long-term stock ownership potential.
Director Steven M. Paul of Rapport Therapeutics received a stock option grant on June 17, 2025. The derivative securities transaction details include:
- Granted 21,850 stock options to purchase common stock
- Exercise price set at $10.95 per share
- Options expire on June 17, 2035
- Vesting occurs at earlier of:
- June 17, 2026
- Next Annual Meeting of Stockholders
The options are subject to continued service requirements and represent a standard director compensation grant. The transaction was reported via Form 4 filing executed by Troy Ignelzi as attorney-in-fact on June 18, 2025.
Director Paul M. Silva of Rapport Therapeutics received a stock option grant for 10,925 shares of common stock on June 17, 2025. The options were granted with the following key terms:
- Exercise price set at $10.95 per share
- Expiration date of June 17, 2035
- Vesting occurs at earlier of:
- June 17, 2026
- Next Annual Meeting of Stockholders
The options were granted at $0 cost to the director and will vest subject to continued service. This represents standard director compensation aligned with the company's equity incentive practices. The Form 4 was filed by Troy Ignelzi as attorney-in-fact on June 18, 2025.